Next Science

Next Science Liabilities

Delisted

The The Liabilities of Next Science (NXS.AX) as of Nov 18, 2026 is 5.77 M USD. In the previous year, The Liabilities was 5.08 M USD — a change of 13.63% (higher).

Liabilities

5.77 MUSD

YoY

13.63%

Last updated:

In 2024, Next Science's total liabilities amounted to 5.77 M USD, a 13.63% difference from the 5.08 M USD total liabilities in the previous year.

The Next Science Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
823,000.00 USD
Jan 1, 2018
10.23 M USD
Jan 1, 2019
3.34 M USD
Jan 1, 2020
4.73 M USD
Jan 1, 2021
2.95 M USD
Jan 1, 2022
4.42 M USD
Jan 1, 2023
5.08 M USD
Jan 1, 2024
5.77 M USD
The Next Science Liabilities history
YEARLiabilitiesYoY
5.77 MUSD+13.63%
5.08 MUSD+14.81%
4.42 MUSD+49.94%
2.95 MUSD-37.57%
4.73 MUSD+41.65%
3.34 MUSD-67.38%
10.23 MUSD+1,142.56%
823,000.00USD+229.73%
249,600.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Next Science Stock analysis

What does Next Science do? Next Science Ltd. generates revenue through the development and commercialization of its XBIO technology, which addresses bacterial biofilm-related infections in human health. The company's product portfolio includes XPERIENCE, a solution for preventing surgical site infections by rinsing away debris and microorganisms, and SurgX Sterile Antimicrobial Gel, designed to reduce surgical and post-surgical infections through sustained antibacterial action for up to five days. Blast X, an antimicrobial wound gel, targets bacterial infections in wounds. These products are sold to healthcare providers and medical facilities seeking effective solutions for bacterial biofilm eradication and infection prevention. The XBIO technology underpins all products, offering non-toxic efficacy against both biofilm and free-floating bacteria. XPERIENCE is used as a pre-surgical rinse, SurgX provides prolonged protection post-surgery, and Blast X treats existing wounds. Healthcare institutions, particularly hospitals and surgical centers, are the primary buyers, leveraging these products to enhance patient outcomes and reduce infection rates. Next Science Ltd. focuses on the healthcare sector, specifically targeting applications where bacterial biofilms pose significant risks. The company's products are positioned for use in surgical settings, wound care, and infection prevention protocols. By addressing critical needs in medical environments, the firm caters to healthcare providers who prioritize non-toxic, effective antimicrobial solutions for patient safety and operational efficiency. Next Science is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Next Science's Liabilities

Next Science's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Next Science's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Next Science's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Next Science's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Next Science’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Next Science stock

The Liabilities of Next Science is 5.77 M USD in 2024.

The Liabilities of Next Science changed from 5.08 M USD to 5.77 M USD, representing a 13.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Next Science since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Next Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Next Science

All Key Metrics — Next Science